细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 5343人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702613, encodeId=cb611e02613d2, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤, objectType=article, longId=186397, objectId=d68418639efd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d68418639efd, replyNumber=0, likeNumber=85, createdTime=2020-05-09, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d68418639efd, moduleTitle=Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d68418639efd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, objectType=article, longId=183346, objectId=525e183346c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525e183346c6, replyNumber=0, likeNumber=70, createdTime=2020-06-02, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525e183346c6, moduleTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525e183346c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702568, encodeId=1ef81e0256814, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2019.V5）, objectType=article, longId=167265, objectId=53a316e2657a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53a316e2657a, replyNumber=0, likeNumber=15, createdTime=2019-09-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53a316e2657a, moduleTitle=NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2019.V5）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53a316e2657a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702601, encodeId=11671e026010f, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, objectType=article, longId=183460, objectId=fde3183460df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde3183460df, replyNumber=0, likeNumber=82, createdTime=2019-12-09, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde3183460df, moduleTitle=FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde3183460df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702580, encodeId=62651e0258081, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：抗生素可抑制皮肤T细胞淋巴瘤的活性, objectType=article, longId=176100, objectId=f54e1e610048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f54e1e610048, replyNumber=0, likeNumber=63, createdTime=2019-08-31, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f54e1e610048, moduleTitle=Blood：抗生素可抑制皮肤T细胞淋巴瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f54e1e610048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702583, encodeId=20e81e02583cb, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：表观遗传修饰剂联合应用可有效治疗外周T细胞淋巴瘤, objectType=article, longId=178703, objectId=280d1e870344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=280d1e870344, replyNumber=0, likeNumber=109, createdTime=2019-09-18, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=280d1e870344, moduleTitle=Blood：表观遗传修饰剂联合应用可有效治疗外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=280d1e870344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702576, encodeId=67541e02576f1, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=治疗复发/难治性结外NK/T细胞淋巴瘤的研究结果, objectType=article, longId=168975, objectId=93db1689e5ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93db1689e5ba, replyNumber=0, likeNumber=103, createdTime=2019-08-06, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93db1689e5ba, moduleTitle=治疗复发/难治性结外NK/T细胞淋巴瘤的研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93db1689e5ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702610, encodeId=97361e0261055, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=68, createdTime=2020-02-07, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702571, encodeId=b63f1e0257108, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=信迪利单抗治疗结外NK/T细胞淋巴瘤，疾病控制率超过85%, objectType=article, longId=168151, objectId=4d2e16815137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d2e16815137, replyNumber=0, likeNumber=67, createdTime=2020-02-06, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d2e16815137, moduleTitle=信迪利单抗治疗结外NK/T细胞淋巴瘤，疾病控制率超过85%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d2e16815137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702575, encodeId=c4371e025757a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=来那度胺在弥漫性大B细胞淋巴瘤中的应用, objectType=article, longId=168705, objectId=eb1e168e0594, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb1e168e0594, replyNumber=0, likeNumber=94, createdTime=2019-10-30, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb1e168e0594, moduleTitle=来那度胺在弥漫性大B细胞淋巴瘤中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb1e168e0594)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702605, encodeId=efc51e02605aa, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=FDA接受ST-001 nanoFenretinide治疗T细胞淋巴瘤的新药申请, objectType=article, longId=185189, objectId=1979185189ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1979185189ec, replyNumber=0, likeNumber=73, createdTime=2020-10-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1979185189ec, moduleTitle=FDA接受ST-001 nanoFenretinide治疗T细胞淋巴瘤的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1979185189ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702585, encodeId=81da1e0258508, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=2019年SOHO：Venetoclax联合Navitoclax治疗复发难治ALL和淋巴母细胞淋巴瘤前景光明, objectType=article, longId=179542, objectId=51df1e9542ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51df1e9542ae, replyNumber=0, likeNumber=118, createdTime=2020-04-13, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51df1e9542ae, moduleTitle=2019年SOHO：Venetoclax联合Navitoclax治疗复发难治ALL和淋巴母细胞淋巴瘤前景光明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51df1e9542ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702604, encodeId=5cf51e026049f, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤, objectType=article, longId=184844, objectId=f4f518484488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4f518484488, replyNumber=0, likeNumber=62, createdTime=2020-06-05, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4f518484488, moduleTitle=Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4f518484488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702572, encodeId=0a201e025723e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=蔡清清教授：盘点弥漫大B细胞淋巴瘤研究进展, objectType=article, longId=168221, objectId=0e2216822192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e2216822192, replyNumber=0, likeNumber=61, createdTime=2019-10-04, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e2216822192, moduleTitle=蔡清清教授：盘点弥漫大B细胞淋巴瘤研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e2216822192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702596, encodeId=bb291e025961f, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2020.V2）, objectType=article, longId=181796, objectId=a46a181e96e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a46a181e96e1, replyNumber=0, likeNumber=15, createdTime=2020-03-20, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a46a181e96e1, moduleTitle=NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2020.V2）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a46a181e96e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702543, encodeId=d8e71e0254365, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, objectType=article, longId=157138, objectId=55df15e138c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55df15e138c5, replyNumber=0, likeNumber=67, createdTime=2019-09-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55df15e138c5, moduleTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55df15e138c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702551, encodeId=f7ae1e0255191, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=2019 BSH更佳实践指南：原发性纵膈B细胞淋巴瘤的管理, objectType=article, longId=159138, objectId=e15f159138c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e15f159138c6, replyNumber=0, likeNumber=20, createdTime=2019-05-03, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e15f159138c6, moduleTitle=2019 BSH更佳实践指南：原发性纵膈B细胞淋巴瘤的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e15f159138c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702552, encodeId=674d1e02552b8, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=2018 JSH实践指南：血液恶性肿瘤——外周T细胞淋巴瘤, objectType=article, longId=159564, objectId=19681595649e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19681595649e, replyNumber=0, likeNumber=20, createdTime=2019-10-17, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19681595649e, moduleTitle=2018 JSH实践指南：血液恶性肿瘤——外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19681595649e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702540, encodeId=06761e02540cf, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=CLIN CANCER RES：Alisertib联合利妥昔单抗或利妥昔单抗/长春新碱治疗B细胞淋巴瘤, objectType=article, longId=156279, objectId=a9f81562e9c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9f81562e9c5, replyNumber=0, likeNumber=69, createdTime=2019-11-06, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9f81562e9c5, moduleTitle=CLIN CANCER RES：Alisertib联合利妥昔单抗或利妥昔单抗/长春新碱治疗B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9f81562e9c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702594, encodeId=27381e025946c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔, objectType=article, longId=180451, objectId=021e180451ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=021e180451ba, replyNumber=0, likeNumber=57, createdTime=2019-10-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=021e180451ba, moduleTitle=【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=021e180451ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤

2020-05-09

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定

2020-06-02

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2019.V5）

2019-09-26

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤

2019-12-09

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：抗生素可抑制皮肤T细胞淋巴瘤的活性

2019-08-31

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：表观遗传修饰剂联合应用可有效治疗外周T细胞淋巴瘤

2019-09-18

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

治疗复发/难治性结外NK/T细胞淋巴瘤的研究结果

2019-08-06

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-02-07

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

信迪利单抗治疗结外NK/T细胞淋巴瘤，疾病控制率超过85%

2020-02-06

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

来那度胺在弥漫性大B细胞淋巴瘤中的应用

2019-10-30

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

FDA接受ST-001 nanoFenretinide治疗T细胞淋巴瘤的新药申请

2020-10-21

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

2019年SOHO：Venetoclax联合Navitoclax治疗复发难治ALL和淋巴母细胞淋巴瘤前景光明

2020-04-13

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤

2020-06-05

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

蔡清清教授：盘点弥漫大B细胞淋巴瘤研究进展

2019-10-04

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2020.V2）

2020-03-20

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择

2019-09-26

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

2019 BSH更佳实践指南：原发性纵膈B细胞淋巴瘤的管理

2019-05-03

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

2018 JSH实践指南：血液恶性肿瘤——外周T细胞淋巴瘤

2019-10-17

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

CLIN CANCER RES：Alisertib联合利妥昔单抗或利妥昔单抗/长春新碱治疗B细胞淋巴瘤

2019-11-06

智智灵药 (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔

2019-10-04

科室
- - 订阅+
  - 更多科室
工具
服务